Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses
This study evaluated HE4 and ROMA for preoperative diagnosis of adnexal masses, finding HE4 improved accuracy over CA 125, particularly in cases of endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
The provided text does not contain the actual content of the research paper titled "Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses." Instead, the input consists of unrelated Polish blog snippets covering topics such as orthopedic surgeon reviews, diabetic diets, liver health supplements, lymphocyte biology, labor induction, FSH hormones, amniocentesis, perinatology, and lubricant selection. Consequently, no study population, methodology, or key findings regarding HE4 or ROMA biomarkers can be extracted from the available material. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
1,862 characters
· extracted from
oa-html
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts 2009
- The Utility of Human Epididymal Protein 4, Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and Endometriosis 2012
- No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting 2011
References (17)
- No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting via openalex
- Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts via openalex
- The Utility of Human Epididymal Protein 4, Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and Endometriosis via openalex
- W2051039914 via openalex
- W2062715296 via openalex
- W2071020286 via openalex
- W2072755146 via openalex
- W2072942199 via openalex
- W2080203245 via openalex
- W2089433134 via openalex
- W2095459904 via openalex
- W2117275438 via openalex
- W2127162013 via openalex
- W1967743734 via openalex
- W2316511287 via openalex
- W1980181125 via openalex
- W2021836342 via openalex
Source provenance
- europepmc
- last seen: 2026-09-27T09:11:36.575535+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:17:52.213533+00:00